SLP

Simulations Plus Inc. (SLP) | Rumor.io

Simulations Plus

SLP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,247

Bullish sentiment (50-day avg)100%

Price to earnings ratio46.1

Market capitalization373.8M

Earnings per share0.4

Dividend yield (TTM)1.3%

Revenue (annual)79.2M

Net income (annual)-64.7M

Social

What share of all stock conversation is about SLP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 6

Simulations Plus ($SLP) partnered with NVIDIA to develop GPU-accelerated, AI-assisted modeling workflows for pharmaceutical development.
The partnership aims to improve the efficiency and accuracy of drug development models.
Institutional ownership of $SLP is high at 74.62%, with a relatively low number of floating shares.

Generated by AI

Sentiment

Of the messages about SLP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.56% +7.05
Bearish	—	—	—	9.44% -7.05

May 6

The company's institutional ownership is high at 74.62%, which may limit the number of tradable shares.
The company's float is relatively low at 16.7M shares, which could lead to a multi-bagger run if it gets above $20 or $25.
The company's small float size may make it vulnerable to being crushed by big boys who are already holding positions in the 19s.

Generated by AI

Topics

Of the messages about SLP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	55.41%
Analysts	—	0%	0%	3.18%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	15.92%
Macro	—	0%	0%	1.91%
Technical Analysis	—	0%	0%	23.57%

Community

Of the messages about SLP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	69.06%
Newcomers	—	100%	100%	30.94%

Regulars· Jul 14

Simulations Plus $SLP reported Q2 earnings, beating adjusted EPS estimates by 137% with $0.45 vs $0.07 est, and revenue up 10% YoY with $20.4M vs $20.9M est.
$SLP guidance was updated, with FY25 EPS lowered to $0.93-$1.06 and FY revenue guidance reaffirmed at $76-80M.
$SLP Q3 adjusted EPS was $0.45c, beating consensus estimates, and revenue rose 9.8% YoY, with $20.4M in sales.

Newcomers· Jul 15

The newcomer is focused on the revenue and EPS metrics for SLP, noting a 10% increase in revenue and a 137% increase in adjusted EPS over the multi-year period.
The newcomer is highlighting the Q3 earnings call for SLP, which reported a 10% increase in revenue and a 137% increase in adjusted EPS, but also a significant impairment in GAAP EPS due to a $77.2 million write-down.
The newcomer is discussing the sentiment around SLP, noting a very positive sentiment with a high multiple (P/E 49) and strong analyst growth forecasts (15.6% YoY), driven by continued analyst upgrades and strong top-line growth.

Generated by AI

RESEARCH TRIANGLE PARK, N.C., September 17, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technolog

12d agoYahoo Finance

Simulations Plus Shareholders Approve Merger with Altaris Affiliate

Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Simulations Plus clears antitrust review for Altaris acquisition

1mo agoInvesting.com

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C., August 13, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC.

1mo agoYahoo Finance

Simulations Plus CRO John DiBella sells $18,360 in stock

1mo agoInvesting.com

Also Discussed

Investors talking about SLP also mention

#	Name	Attention
1	Schrödinger, Inc.SDGR	0%-0.01
2	WD-40 CompanyWDFC	0%new
3	PriceSmart, Inc.PSMT	0%new
4	HealthEquity, Inc.HQY	0%new
5	Medpace Holdings, Inc.MEDP	0%+0
6	SAGA - Sagaliam Acquisition Corp.	——
7	Willdan Group, Inc.WLDN	0%new
8	Avanos Medical Inc.AVNS	0%0
9	Certara Inc.CERT	0%0
10	Sibanye Stillwater Ltd. ADRSBSW	0%0

Simulations Plus Inc.

Healthcare
Health Information Services

Simulations Plus Inc. is a healthcare technology company that develops modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and life sciences industries. The company’s products help customers support drug discovery, preclinical research, clinical development, regulatory submissions, and commercialization by improving how drug behavior and molecular properties are analyzed. Its software portfolio includes tools used for biosimulation, pharmacokinetic and pharmacodynamic modeling, and prediction of absorption, distribution, metabolism, excretion, and toxicity characteristics. Simulations Plus also provides professional services that complement its software by helping clients apply model-informed approaches across the drug development process. The company serves a global customer base that includes pharmaceutical companies, biotech firms, and research organizations.

Website

Location

800 Park Offices Drive

Research Triangle Park, NC, 27709

United States

Social

What share of all stock conversation is about SLP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 6

Simulations Plus ($SLP) partnered with NVIDIA to develop GPU-accelerated, AI-assisted modeling workflows for pharmaceutical development.
The partnership aims to improve the efficiency and accuracy of drug development models.
Institutional ownership of $SLP is high at 74.62%, with a relatively low number of floating shares.

Generated by AI

Sentiment

Of the messages about SLP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.56% +7.05
Bearish	—	—	—	9.44% -7.05

May 6

The company's institutional ownership is high at 74.62%, which may limit the number of tradable shares.
The company's float is relatively low at 16.7M shares, which could lead to a multi-bagger run if it gets above $20 or $25.
The company's small float size may make it vulnerable to being crushed by big boys who are already holding positions in the 19s.

Generated by AI

Topics

Of the messages about SLP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	55.41%
Analysts	—	0%	0%	3.18%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	15.92%
Macro	—	0%	0%	1.91%
Technical Analysis	—	0%	0%	23.57%

Community

Of the messages about SLP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	69.06%
Newcomers	—	100%	100%	30.94%

Regulars· Jul 14

Simulations Plus $SLP reported Q2 earnings, beating adjusted EPS estimates by 137% with $0.45 vs $0.07 est, and revenue up 10% YoY with $20.4M vs $20.9M est.
$SLP guidance was updated, with FY25 EPS lowered to $0.93-$1.06 and FY revenue guidance reaffirmed at $76-80M.
$SLP Q3 adjusted EPS was $0.45c, beating consensus estimates, and revenue rose 9.8% YoY, with $20.4M in sales.

Newcomers· Jul 15

The newcomer is focused on the revenue and EPS metrics for SLP, noting a 10% increase in revenue and a 137% increase in adjusted EPS over the multi-year period.
The newcomer is highlighting the Q3 earnings call for SLP, which reported a 10% increase in revenue and a 137% increase in adjusted EPS, but also a significant impairment in GAAP EPS due to a $77.2 million write-down.
The newcomer is discussing the sentiment around SLP, noting a very positive sentiment with a high multiple (P/E 49) and strong analyst growth forecasts (15.6% YoY), driven by continued analyst upgrades and strong top-line growth.

Generated by AI

Simulations Plus

Social

May 6

Sentiment

May 6

Topics

Community

Regulars· Jul 14

Newcomers· Jul 15

News

Simulations Plus Says FDA's Cosmetics Branch Adopts ADMET Predictor

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Simulations Plus Shareholders Approve Merger with Altaris Affiliate

Simulations Plus clears antitrust review for Altaris acquisition

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Simulations Plus CRO John DiBella sells $18,360 in stock

Also Discussed

Simulations Plus Inc.

Company Information

Location

News

Simulations Plus Says FDA's Cosmetics Branch Adopts ADMET Predictor

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Simulations Plus Shareholders Approve Merger with Altaris Affiliate

Simulations Plus clears antitrust review for Altaris acquisition

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Simulations Plus CRO John DiBella sells $18,360 in stock

Also Discussed

Social

May 6

Sentiment

May 6

Topics

Community

Regulars· Jul 14

Newcomers· Jul 15